Serum Concentrations of Osteogenesis/Osteolysis-Related Factors and Micro-RNA Expression in ST-Elevation Myocardial Infarction

Table 4

Comparison of osteogenesis and osteolysis factors at the baseline and after 3-month follow-up.

Factor (unit)	Baseline concentration	3-month follow-up concentration	value
DKK-1 (pg/ml)	492 (405–630)	430 (358–499)	0.11
TNF-α (pg/ml)	1.0 (0.69–1.21)	1.0 (0.82–1.67)	0.29
OPG (pg/ml)	155 (127–182)	155 (137–196)	0.62
OCN (ng/ml)	5.39 (3.88–6.76)	7.20 (4.45–8.76)	0.06
OPN (ng/ml)	17.15 (12.77–22.01)	13.72 (9.68–17.91)	0.10
NT-proANP (ng/ml)	5.52 (4.74–7.66)	5.12 (3.79–8.0)	0.63
PCSK9 (ng/ml)	66.20 (51.77–94.91)	71.49 (54.68–95.47)	0.60
TSP-2 (ng/ml)	25.52 (20.30–40.69)	23.47 (15.78–38.64)	0.39
TRAIL (pg/ml)	62 (61–65)	67 (62–78)	0.10
FGF-23 (pg/ml)	BDL	BDL
sRANKL (pg/ml)	BDL	BDL

BDL, below detection level; DKK-1, Dickkopf-related protein 1; FGF-23, fibroblast growth factor 23; NT-proANP, N-terminal atrial natriuretic peptide; OPG, osteoprotegerin; OCN, osteocalcin; OPN, osteopontin; PCSK9, proprotein convertase subtilisin/kexin type 9; sRANKL, soluble receptor activator of nuclear factor-kappaB ligand; TNF-α, tumor necrosis factor alpha; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TSP-2, thrombospondin-2.